Catheter Precision 宣布其 VIVO 无创标测系统治疗瘢痕相关室性心动过速的手术成功率为 90%。 Catheter Precision announces 90% procedural success rate for its VIVO non-invasive mapping system in treating scar-related ventricular tachycardia.

Catheter Precision 宣布了其 VIVO 无创标测系统的更新，该系统最近在欧洲心脏病学会会议上重点介绍了该系统。 Catheter Precision has announced updates on its VIVO non-invasive mapping system, recently highlighted at the European Society of Cardiology meeting. 一项研究显示,与痕相关的腹腔动脉短心症患者的手术成功率为90%. A study showcased a 90% procedural success rate for patients with scar-related ventricular tachycardia. 获得FDA和CE批准的VIVO有助于识别心室失常的原因,改善工作流程并缩短手术时间. VIVO, which has FDA and CE approvals, helps identify ventricular arrhythmia origins, enhancing workflow and reducing procedure time. 该公司正在扩大在美国和国际上的存在,有超过25个中心对VIVO感兴趣。 The company is expanding its presence in the U.S. and internationally, with over 25 centers interested in VIVO.